Free Trial
→ INSANE DRONE FOOTAGE (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$19.12
-3.0%		$25.53
$18.39
▼
$30.96
$3.29B0.882.55 million shs1.67 million shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$66.39
-1.1%		$72.75
$52.75
▼
$93.42
$12.98B0.972.98 million shs2.06 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$121.84
+0.3%		$109.06
$61.22
▼
$122.45
$13.83B0.882.92 million shs2.08 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$9.18
-8.2%		$8.57
$1.95
▼
$12.43
$9.73B0.0215.89 million shs21.48 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
0.00%-3.34%-30.35%-25.31%-12.05%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%+1.59%-1.37%-18.42%+17.23%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
0.00%+10.34%+11.09%+56.59%+83.60%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
0.00%-12.65%+8.51%+19.53%+255.81%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$19.12
-3.0%		$25.53
$18.39
▼
$30.96
$3.29B0.882.55 million shs1.67 million shs
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$66.39
-1.1%		$72.75
$52.75
▼
$93.42
$12.98B0.972.98 million shs2.06 million shs
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$121.84
+0.3%		$109.06
$61.22
▼
$122.45
$13.83B0.882.92 million shs2.08 million shs
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$9.18
-8.2%		$8.57
$1.95
▼
$12.43
$9.73B0.0215.89 million shs21.48 million shs
Don't Wait for the OpenAI IPO Cover
Don't Wait for the OpenAI IPO

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
0.00%-3.34%-30.35%-25.31%-12.05%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
0.00%+1.59%-1.37%-18.42%+17.23%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
0.00%+10.34%+11.09%+56.59%+83.60%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
0.00%-12.65%+8.51%+19.53%+255.81%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
2.72
Moderate Buy$31.3463.92% Upside
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
2.88
Moderate Buy$104.7557.78% Upside
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.77
Moderate Buy$99.55-18.30% Downside
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
2.71
Moderate Buy$16.0074.29% Upside

Current Analyst Ratings Breakdown

Latest ACAD, BBIO, HALO, and IBRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/16/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access to unlock brokerage rankings
Set Price Target$130.00
10/15/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$82.00 ➝ $92.00
10/15/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingBuy$15.00
10/14/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Jefferies Financial Group Inc. logo
Jefferies Financial Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$12.00 ➝ $14.00
10/14/2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight$16.00
10/14/2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeStrong-Buy
10/13/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
UBS Group AG logo
UBS Group
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeBuy ➝ Neutral$49.00 ➝ $23.00
10/13/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeHold ➝ Strong-Buy
10/13/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
TD Cowen logo
TD Cowen
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetBuy$105.00 ➝ $130.00
10/8/2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
Royal Bank Of Canada logo
Royal Bank Of Canada
Subscribe to MarketBeat All Access to unlock brokerage rankings
Lower Price TargetOutperform$37.00 ➝ $36.00
10/8/2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
JPMorgan Chase & Co. logo
JPMorgan Chase & Co.
Subscribe to MarketBeat All Access to unlock brokerage rankings
Boost Price TargetNeutral$70.00 ➝ $78.00
(Data available from 10/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$1.14B2.89$0.89 per share21.55$7.25 per share2.64
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
$713.07M18.20N/AN/A($10.77) per share-6.16
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.40B9.90$4.77 per share25.54$0.42 per share290.10
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
$113.29M85.88N/AN/A($0.51) per share-18.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$391M$2.228.6119.51N/A33.42%9.03%6.79%11/4/2026 (Estimated)
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$724.93M-$3.57N/AN/AN/A-97.03%N/A-61.19%10/28/2026 (Estimated)
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$316.89M$3.3536.3712.450.4624.86%260.98%23.91%11/2/2026 (Estimated)
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$351.40M-$0.97N/AN/AN/A-598.55%N/A-51.65%11/3/2026 (Estimated)

Latest ACAD, BBIO, HALO, and IBRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/4/2026Q3 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.1987N/AN/AN/A$332.47 millionN/A
11/3/2026Q3 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.07N/AN/AN/A$59.23 millionN/A
11/2/2026Q3 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$2.30N/AN/AN/A$490.85 millionN/A
10/28/2026Q3 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5694N/AN/AN/A$281.10 millionN/A
8/10/2026Q2 2026
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
-$0.5756-$0.78-$0.2044-$0.78$220.91 million$243.68 million
8/6/2026Q2 2026
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
$1.79$2.28+$0.49$1.90$402.28 million$481.00 million
8/4/2026Q2 2026
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
$0.0682$0.18+$0.1119$0.18$296.55 million$308.00 million
8/4/2026Q2 2026
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
-$0.08-$0.22-$0.14-$0.22$49.70 million$51.24 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/AN/AN/AN/AN/A
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/AN/AN/AN/AN/A
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
N/AN/AN/AN/AN/A
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
N/A
3.39
3.30
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
N/A
1.23
1.17
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
13.50
2.71
2.31
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
N/A
5.72
5.70

Institutional Ownership

CompanyInstitutional Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
96.71%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
99.85%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
97.79%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
8.58%

Insider Ownership

CompanyInsider Ownership
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
26.20%
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
14.23%
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
2.50%
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
66.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
ACADIA Pharmaceuticals Inc. stock logo
ACAD
ACADIA Pharmaceuticals
798172.31 million127.16 millionOptionable
BridgeBio Pharma, Inc. stock logo
BBIO
BridgeBio Pharma
839195.49 million167.67 millionOptionable
Halozyme Therapeutics, Inc. stock logo
HALO
Halozyme Therapeutics
423113.50 million110.66 millionOptionable
ImmunityBio, Inc. stock logo
IBRX
ImmunityBio
6911.06 billion359.28 millionOptionable

Recent News About These Companies

FY2027 EPS Estimates for ImmunityBio Raised by HC Wainwright
October 18 at 1:58 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31129637
H.C. Wainwright keeps USD 15.00 target for ImmunityBio stock
October 17 at 11:03 PM  |  ad-hoc-news.deA
HC Wainwright Reaffirms Buy Rating for ImmunityBio (NASDAQ:IBRX)
October 17 at 3:34 AM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31128195
ImmunityBio (IBRX) Shares Drop 7.25% as Investors Overlook 71% Response Rate in Bladder Cancer Trial
October 16 at 5:39 PM  |  moneycheck.comM
ImmunityBio: Jury May Still Be Out On Anktiva Despite Latest NMIBC Win
October 16 at 5:39 PM  |  seekingalpha.comhttps://seekingalpha.com/article/4954800-immunitybio-jury-may-still-be-out-on-anktiva-despite-latest-nmibc-win
Investors Buy Large Volume of ImmunityBio Call Options (NASDAQ:IBRX)
October 16 at 1:39 PM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/options-investors-buy-large-volume-of-immunitybio-call-options-nasdaq-ibrx-2026-10-16/
ImmunityBio, Inc. (IBRX) Stock: Slides 7.25% Despite Major Breakthrough in Bladder Cancer Treatment
October 16 at 12:51 PM  |  blockonomi.comhttps://blockonomi.com/immunitybio-inc-ibrx-stock-slides-7-25-despite-major-breakthrough-in-bladder-cancer-treatment/
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With ...
October 16 at 12:38 PM  |  marketscreener.comM
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
October 16 at 11:49 AM  |  businesswire.comhttps://www.businesswire.com/news/home/20261016061704/en/immunitybio-reports-phase-3-data-showing-84-cystectomy-avoidance-at-three-years-and-complete-responses-beyond-53-months-with-anktiva%c2%ae-plus-bcg-in-bcg-unresponsive-nmibc-with-cis-with-or-without-papillary-tumors/
IBRX stock eyes weekly slump despite Anktiva FDA win — retail stays cautious ahead of founder’s trial talk
October 16 at 7:38 AM  |  msn.comhttps://www.msn.com/en-in/news/other/ibrx-stock-eyes-weekly-slump-despite-anktiva-fda-win-retail-stays-cautious-ahead-of-founder-s-trial-talk/ar-AA2efFsg
HC Wainwright Increases Earnings Estimates for ImmunityBio
October 16 at 6:27 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-hc-wainwright-increases-earnings-estimates-for-immunitybio-2026-10-16/
Jefferies lifts target for ImmunityBio stock to USD 14.00
October 16 at 1:09 AM  |  ad-hoc-news.deA
ImmunityBio, Inc. Announces FDA Expands ANKTIVA Approval For BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer To Cover Both Papillary And CIS Disease
October 15 at 3:02 PM  |  marketscreener.comM
ImmunityBio (IBRX) Stock: Climbs as FDA Expands ANKTIVA Approval for Bladder Cancer
October 15 at 3:02 PM  |  blockonomi.comhttps://blockonomi.com/immunitybio-ibrx-stock-climbs-as-fda-expands-anktiva-approval-for-bladder-cancer/
FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer
October 15 at 2:00 PM  |  zacks.comhttps://www.zacks.com/stock/news/3008851/fda-expands-immunitybio-s-anktiva-label-in-bladder-cancer?cid=cs-stocknewsapi-ft-analyst_blog|company_news_medical_sector-3008851
ImmunityBio (NASDAQ:IBRX) Given "Buy" Rating at HC Wainwright
October 15 at 8:12 AM  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-immunitybio-nasdaq-ibrx-given-buy-rating-at-hc-wainwright-2026-10-15/
ImmunityBio Stock Climbs Thursday: What's Going On?
October 15 at 7:01 AM  |  benzinga.comhttps://www.benzinga.com/trading-ideas/movers/26/10/62376351/immunitybio-stock-climbs-thursday-whats-going-on?utm_source=snapi
FDA Expands Indication for ImmunityBio's Bladder Cancer Drug
October 14, 2026  |  marketscreener.comM
IBRX stock rallies after FDA clears broader Anktiva use in bladder cancer months ahead of deadline
October 14, 2026  |  msn.comhttps://www.msn.com/en-in/news/other/ibrx-stock-rallies-after-fda-clears-broader-anktiva-use-in-bladder-cancer-months-ahead-of-deadline/ar-AA2eeEWP
SLS, IBRX Rise Premarket: Funds Raise Their Bets As J&J Stays ‘On The Lookout’ For Deals
October 14, 2026  |  stocktwits.comS
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
October 14, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261014705251/en/fda-expands-anktiva%c2%ae-approval-for-bcg-unresponsive-non-muscle-invasive-bladder-cancer-to-cover-both-papillary-and-cis-disease/

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACADIA Pharmaceuticals stock logo

ACADIA Pharmaceuticals NASDAQ:ACAD

$19.12 -0.59 (-2.99%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$19.23 +0.11 (+0.56%)
As of 10/16/2026 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

BridgeBio Pharma stock logo

BridgeBio Pharma NASDAQ:BBIO

$66.39 -0.74 (-1.10%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$65.83 -0.56 (-0.85%)
As of 10/16/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Halozyme Therapeutics stock logo

Halozyme Therapeutics NASDAQ:HALO

$121.84 +0.33 (+0.27%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$120.69 -1.15 (-0.94%)
As of 10/16/2026 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; rilpivirine, cabotegravir, and N6LS BNAB for the treatment of HIV; ocrelizumab for multiple sclerosis; XYOSTED, an injection for SC administration of testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of chronic lymphocytic leukemia; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergic reactions; nivolumab+relatlimab and ANTI-TIM3 for the treatment of solid tumors; ARGX-117 for multifocal motor neuropathy; atezolizumab; nivolumab; afgartigimod; teriparatide injections; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

ImmunityBio stock logo

ImmunityBio NASDAQ:IBRX

$9.18 -0.82 (-8.20%)
Closing price 10/16/2026 04:00 PM Eastern
Extended Trading
$9.20 +0.02 (+0.17%)
As of 10/16/2026 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas